Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer

Eran Brauner; Viswanath Gunda; Pierre Vanden Borre; DAVID ZURAKOWSKI; Yon Seon Kim; Kate Virginia Dennett; Salma Amin; Gordon James Freeman; Sareh Parangi

doi:10.18632/oncotarget.7839

journal article Mar 02, 2016

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer

Eran Brauner Viswanath Gunda Pierre Vanden Borre DAVID ZURAKOWSKI

Yon Seon Kim Kate Virginia Dennett Salma Amin Gordon James Freeman Sareh Parangi

Oncotarget Vol. 7 No. 13 pp. 17194-17211 · Impact Journals, LLC

View at Publisher Save 10.18632/oncotarget.7839

Topics

No keywords indexed for this article. Browse by subject →

References

59

[1]

Jemal "Cancer statistics, 2013" CA (2013)

[2]

Hay "Thyroid cancer nodal metastases: biologic significance and therapeutic considerations" Surgical oncology clinics of North America (1996) 10.1016/s1055-3207(18)30404-6

[3]

Haglund "Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients" Oncology (2010) 10.1159/000322640

[4]

Jarzab "Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer" Jama (2013) 10.1001/jama.2013.3190

[5]

Cancer Genome Atlas Research Network "Integrated genomic characterization of papillary thyroid carcinoma" Cell (2014) 10.1016/j.cell.2014.09.050

[6]

Sherman "Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation" Thyroid (2013) 10.1089/thy.2013.0057

[7]

Glaspy "BRAF V600E inhibition in anaplastic thyroid cancer" The New England journal of medicine (2013) 10.1056/nejmc1215697

[8]

Flaherty "BRAF in melanoma: current strategies and future directions" Clinical cancer research (2013) 10.1158/1078-0432.ccr-13-0779

[9]

Hirth "Vemurafenib: the first drug approved for BRAF-mutant cancer" Nature reviews Drug discovery (2012) 10.1038/nrd3847

[10]

Pardoll "The blockade of immune checkpoints in cancer immunotherapy" Nature reviews Cancer (2012) 10.1038/nrc3239

[11]

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

Daniel Sanghoon Shin, Antoni Ribas

Current Opinion in Immunology 2015 10.1016/j.coi.2015.01.006

[12]

Freeman "Combination cancer immunotherapy and new immunomodulatory targets" Nature reviews Drug discovery (2015) 10.1038/nrd4591

[13]

Hodi "Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1" Clinical cancer research (2012) 10.1158/1078-0432.ccr-12-1362

[14]

Inhibitory B7-family molecules in the tumour microenvironment

Weiping Zou, Lieping Chen

Nature Reviews Immunology 2008 10.1038/nri2326

[15]

Kwon "Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target" Proceedings of the National Academy of Sciences of the United States of America (2004) 10.1073/pnas.0406351101

[16]

Tokura "Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma" Cancer (2010) 10.1002/cncr.24899

[17]

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow et al.

New England Journal of Medicine 2012 10.1056/nejmoa1200694

[18]

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al.

New England Journal of Medicine 2012 10.1056/nejmoa1200690

[19]

Ward "Differentiated thyroid carcinomas and their B7H1 shield" Future Oncol (2013) 10.2217/fon.13.89

[20]

Ward "Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation" Endocrine-related cancer (2013)

[21]

Haugen "Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer" The Journal of clinical endocrinology and metabolism (2012) 10.1210/jc.2011-3428

[22]

French "PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer" Cancer immunology research (2015) 10.1158/2326-6066.cir-14-0201

[23]

Epstein "BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration" Thyroid (2014) 10.1089/thy.2014.0134

[24]

Freeman "Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production" J Immunol (2003) 10.4049/jimmunol.170.3.1257

[25]

Leonard "Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells" Microcirculation (2002) 10.1080/713774061

[26]

Wiendl "Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis" Journal of neuroimmunology (2004) 10.1016/j.jneuroim.2004.06.013

[27]

Sharpe "PD-1 and its ligands in tolerance and immunity" Annual review of immunology (2008) 10.1146/annurev.immunol.26.021607.090331

[28]

Parangi "BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression" Cancer research (2011) 10.1158/0008-5472.can-10-3844

[29]

Parangi "The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma" Thyroid (2014) 10.1089/thy.2013.0483

[30]

Wargo "Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade" Cancer immunology research (2014) 10.1158/2326-6066.cir-13-0215

[31]

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid, Caroline Robert, Adil Daud et al.

New England Journal of Medicine 2013 10.1056/nejmoa1305133

[32]

Hammers "Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial" Journal of clinical oncology (2015) 10.1200/jco.2014.59.0703

[33]

Lizee "BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma" Clinical cancer research (2013) 10.1158/1078-0432.ccr-12-1630

[34]

de las Morenas "Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets" Pathology oncology research (2015) 10.1007/s12253-014-9876-5

[35]

Parangi "Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer" Oncotarget (2014) 10.18632/oncotarget.2130

[36]

BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy

Richard C. Koya, Stephen Mok, Nicholas Otte et al.

Cancer Research 2012 10.1158/0008-5472.can-11-2837

[37]

Smyth "Host immunity contributes to the anti-melanoma activity of BRAF inhibitors" The Journal of clinical investigation (2013) 10.1172/jci66236

[38]

Hodi "The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition" Clinical cancer research (2013) 10.1158/1078-0432.ccr-12-2731

[39]

Uchiyama "B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma" Cancer science (2009) 10.1111/j.1349-7006.2009.01302.x

[40]

Marais "Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF" Cell (2010) 10.1016/j.cell.2009.12.040

[41]

Jaiswal "RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth" Nature (2010) 10.1038/nature08833

[42]

Wargo "Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma" Cancer biology & medicine (2014)

[43]

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

James S. Wilmott, Georgina V. Long, Julie R. Howle et al.

Clinical Cancer Research 2012 10.1158/1078-0432.ccr-11-2479

[44]

Ribas "Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma" Clinical cancer research (2014) 10.1158/1078-0432.ccr-13-2797

[45]

Antony "Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma" J Immunol (2013) 10.4049/jimmunol.1300271

[46]

Ahmed "Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection" Proceedings of the National Academy of Sciences of the United States of America (2010) 10.1073/pnas.1009731107

[47]

Smyth "Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors" Cancer research (2011) 10.1158/0008-5472.can-11-0096

[48]

Anderson "Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity" The Journal of experimental medicine (2010) 10.1084/jem.20100643

[49]

Chen "Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates" Journal of clinical oncology (2010) 10.1200/jco.2009.26.7609

[50]

Ascierto "Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma" Cancer immunology, immunotherapy (2015) 10.1007/s00262-014-1647-3

Showing 50 of 59 references

Cited By

88

LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway

Xiaoming Wang, Jian Zheng · 2021

Cancer Immunology, Immunotherapy

Metrics

88

Citations

59

References

Details

Published: Mar 02, 2016
Vol/Issue: 7(13)
Pages: 17194-17211

Authors

E

Eran Brauner

Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

V

Viswanath Gunda

Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

P

Pierre Vanden Borre

Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

D

DAVID ZURAKOWSKI

Departments of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Departments of Anesthesia, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA

Y

Yon Seon Kim

Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Surgery, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea

K

Kate Virginia Dennett

Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

S

Salma Amin

Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

G

Gordon James Freeman

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

S

Sareh Parangi

Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Cite This Article

Eran Brauner, Viswanath Gunda, Pierre Vanden Borre, et al. (2016). Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget, 7(13), 17194-17211. https://doi.org/10.18632/oncotarget.7839

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer

You May Also Like